Credit Suisse Group set a $156.00 price target on Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Several other brokerages have also issued reports on JNJ. Morgan Stanley set a $60.00 target price on shares of Berry Global Group and gave the stock a hold rating in a research report on Wednesday, April 17th. Bank of America upgraded shares of First Horizon National from an underperform rating to a neutral rating and set a $16.00 target price for the company in a research report on Tuesday, July 16th. Barclays upped their target price on shares of from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the stock an equal weight rating in a research report on Friday, June 21st. Raymond James reiterated a reduce rating and issued a $48.00 target price (up from $45.00) on shares of Hancock Whitney in a research report on Wednesday, July 17th. Finally, Zacks Investment Research upgraded shares of Jack Henry & Associates from a sell rating to a hold rating in a research report on Wednesday, March 27th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson has a consensus rating of Buy and a consensus price target of $148.56.

Shares of NYSE:JNJ opened at $130.31 on Thursday. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The stock has a fifty day moving average of $138.34. The stock has a market capitalization of $345.98 billion, a price-to-earnings ratio of 15.93, a PEG ratio of 2.20 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.57%. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period in the previous year, the business earned $2.10 earnings per share. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.92%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the stock in a transaction on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.23% of the company’s stock.

A number of institutional investors have recently bought and sold shares of JNJ. Ellenbecker Investment Group raised its stake in shares of Johnson & Johnson by 9.9% during the fourth quarter. Ellenbecker Investment Group now owns 2,364 shares of the company’s stock valued at $305,000 after acquiring an additional 212 shares during the last quarter. Private Trust Co. NA raised its stake in shares of Johnson & Johnson by 9.3% during the fourth quarter. Private Trust Co. NA now owns 59,108 shares of the company’s stock valued at $7,627,000 after acquiring an additional 5,013 shares during the last quarter. Neville Rodie & Shaw Inc. raised its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Neville Rodie & Shaw Inc. now owns 258,914 shares of the company’s stock valued at $33,413,000 after acquiring an additional 2,100 shares during the last quarter. Stillwater Investment Management LLC raised its stake in shares of Johnson & Johnson by 0.7% during the fourth quarter. Stillwater Investment Management LLC now owns 31,117 shares of the company’s stock valued at $4,016,000 after acquiring an additional 216 shares during the last quarter. Finally, Silverleafe Capital Partners LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at about $298,000. 66.85% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is a Special Dividend?

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.